Following the approval of Amylyx’s Relyvrio and the upcoming Biogen/Ionis Tofersen FDA decision on the basis of neurofilament light chain as a surrogate endpoint, the ALS drug development landscape is gaining momentum and positivity. With early indications of potential regulatory firsts, booming pharma investment, and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.

Capturing this, the timely 2nd Annual ALS Drug Development Summit is the only industry-focused conference dedicated to overcoming preclinical clinical challenges currently facing ALS pipelines. This is your must-attend meeting showcasing the latest breakthroughs in ALS in 2023.